Why IMU is a multi multi bagger, page-21332

"I don't think the guy they interviewed - Ben Kikuchi - was the MAST trial complete response patient though."

Extremely good pickup@davybabyk!! At first watch I definitely assumed he was that patient, but there's one or two other things that don't quite fit as well.

In the Channel 7 segment Ben says his work colleagues noticed him being jaundice in "December 2022", presumably he was diagnosed then or soon after.
The recent Imugene announcement here includes the statement "1 Complete Response (CR)* in biliary tract cancer treated at a mid-dose; patient has been in remission for over 430 days". When you take into account that even to qualify for the MAST study, patients have to have been on, and failed at least two other lines of therapy previously the timing just doesn't add up. He simply wouldn't have had time to clock up 430 days cancer free.

In addition to that, I think the patient who achieved a CR was a US patient. I know I'm making some assumptions here, but in their recent presentations Imugene had patient ID's on some of the graphs. Some starting with AU and some starting with US, I'm assuming this is to do with where the patient participated in the study. The patient who achieved the complete response was US02-001.



A great segment for IMU though and feel like others have said they may be trying to help recruitment for the study extension into Bile Duct Cancer.